EPHA2 and prostate cancer: demonstrated that higher levels of EphA2 expression and PI3K activity were associated with VM in more invasive prostate cancer cell lines PC3 and DU-145, but with no significant correlation between EphA2 and PI3K expression levels (53), Luo et al.